You are about to leave the Clinical Value website now.
This study aims to determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in chronic hepatitis B (CHB).
Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, Jang MK, Lee JH, Kim JS, Kim HY, Kim DJ, Lee MS, Park CK…
This study aims to evaluate the diagnostic efficacy of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage hepatitis virus B (HBV) related hepatocellular carcinoma (HCC).
Wang X, Zhang W, Liu Y, Gong W, Sun P, Kong X, Yang M, Wang Z…
This review article provides a comprehensive overview of the indications and rationale for HCC surveillance, currently available surveillance methods and their utilization, effectiveness, and limitations, as well as novel surveillance tools which are emerging as alternatives.
Ahn JC, Lee YT, Agopian VG, Zhu Y, You S, Tseng HR, Yang J…
PIVKA-II has been extensively studied as a biomarker in HCC. However, its diagnostic capability varies across HCC studies. This study aimed to compare the performance of PIVKA-II with AFP in the diagnosis of HCC.
Xing H, Zheng YJ, Han J, Zhang H, Li ZL, Lau WY, Shen F, Yang T…
This study aims to determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its relationship with vascular invasion and HBV DNA.
Wu J, Xiang Z, Bai L, He L, Tan L, Hu M, Ren Y…
In this video, Dr Bao Toan Nguyen from MEDIC-LAB Ho Chi Minh discusses how PIVKA-II can complement AFP in assisting clinicians in the early detection and overall management of HCC, and his experience with PIVKA-II at MEDIC-LAB. …